AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Phreesia, a patient intake management software developer, has seen its stock rise after Mizuho launched coverage with an Outperform recommendation. The recommendation is based on potential in the company's network solutions business, which generated $121.6M in revenue for 2022. Mizuho expects Phreesia's network solutions business to continue to grow, driven by increasing demand for patient engagement solutions.
Phreesia (NYSE: PHR), a developer of patient intake management software, experienced a significant stock rise following Mizuho's launch of its coverage with an Outperform recommendation. The recommendation is centered on the company's network solutions business, which generated $121.6 million in revenue for 2022 [1]. Mizuho analyst Steven Valiquette highlighted the potential of this business, which provides patients with customized health content and allows Phreesia to capitalize on pharma digital marketing expenditure. The network solutions business has demonstrated robust growth, with revenue increasing by ~29% year-over-year (YoY) in 2025 compared to ~27% YoY growth in 2024.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet